ID: ALA3916767

Max Phase: Preclinical

Molecular Formula: C24H23ClFN3O4

Molecular Weight: 471.92

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(N[C@@H](Cc1ccc(F)cc1)C(=O)C(=O)N1CCC(O)CC1)c1cc2cc(Cl)ccc2[nH]1

Standard InChI:  InChI=1S/C24H23ClFN3O4/c25-16-3-6-19-15(12-16)13-21(27-19)23(32)28-20(11-14-1-4-17(26)5-2-14)22(31)24(33)29-9-7-18(30)8-10-29/h1-6,12-13,18,20,27,30H,7-11H2,(H,28,32)/t20-/m0/s1

Standard InChI Key:  VCKKIPCWUZKXJQ-FQEVSTJZSA-N

Associated Targets(Human)

Liver glycogen phosphorylase 1040 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Glycogen phosphorylase, muscle form 1331 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 471.92Molecular Weight (Monoisotopic): 471.1361AlogP: 2.85#Rotatable Bonds: 6
Polar Surface Area: 102.50Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 2.76CX LogD: 2.76
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.48Np Likeness Score: -1.02

References

1. Galal SA, Khattab M, Andreadaki F, Chrysina ED, Praly JP, Ragab FAF, El Diwani HI..  (2016)  Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors.,  24  (21): [PMID:27624527] [10.1016/j.bmc.2016.08.069]

Source